Moderna Inc. said on Thursday it had completed the enrollment of 30,000 participants in a late-stage study testing its experimental coronavirus vaccine, with over a third of the participants from communities of color.
Over 25,650 participants have so far received their second shot of the vaccine candidate, mRNA-1273, the company said.
Moderna said its study includes more than 11,000 participants from minority communities, including 6,000 Hispanic or Latin-American participants and more than 3,000 Black or African-American participants.
The company said it would evaluate the study’s risks and benefits before submitting an emergency-use application for the vaccine to the U.S. health regulator.
The U.S. Food and Drug Administration requires at least two months of safety data after a full vaccination regime to review applications for emergency use authorization of an experimental vaccine.
The Moderna trials are one of several vaccines being developed or tested in the St. Louis area.
Moderna was the first U.S.-based company to enter clinical trials for its coronavirus vaccine in March. Early testing on healthy volunteers showed promising results, indicating that the vaccine stimulated an immune response and did not cause severe side effects.
St. Louis University announced in August it had begun recruiting volunteers to test the Moderna vaccine.
Daily updates on the latest news in the St. Louis business community.